TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05883358

Intervention type: DRUG
Intervention: Clonidine, Buprenorphine
Description: Each patient receives rotational treatment using Buprenorphine 5cmg/hr patch; or Clonidine tablet 0.1mg 4hourly; or combined Clonidine tablet 0.1mg 4hourly + Buprenorphine 5cmg/hr patch.
Study: NCT04049253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphate Buffer Solution
Description: Phosphate-buffered saline (abbreviated PBS) is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body (isotonic).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffer Solution
Description: Phosphate-buffered saline (abbreviated PBS) is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body (isotonic).
Study: NCT01380873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period I : HKB0701, Period II : HKB0701 and SLM0807, Period III : CJ30001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period I : HKB0701 and SLM0807, Period II : CJ30001, Period III : HKB0701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period I : CJ30001, Period II : HKB0701, Period III : HKB0701 and SLM0807
Study: NCT00799604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clevidipine
Description: Clevidipine (0.5mg/mL in 20% lipid emulsion) was administered as an IV bolus (\<5 sec) by rapid injection for Bolus 1 and for Bolus 2, if second bolus dose was administered, directly into a peripheral venous catheter followed by a normal saline flush (10mL).
Study: NCT00481000

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Dialectical Cognitive Therapy
Description: Dialectical Behavior Therapy in Combination with Traumafocused CBT
Study: NCT01264588

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Topical calcium glycerophosphate lotion
Description: 2g once daily for 6 weeks (post-op day 3 thru 42)
Study: NCT03737721

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Avelumab and Radical radiotherapy
Description: A single-arm, interventional study combining Avelumab with radical radiotherapy. Avelumab will be delivered on a 14-day cycle, with the first cycle administered 14 days in advance of the radiation therapy start date; 63-66 Gy radiation will be delivered over 30 daily fractions concurrent with an additional 4 cycles of Avelumab
Study: NCT02389348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSM265
Description: Single oral doses of DSM265
Study: NCT04042376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be administered orally, once daily, at a dose of 420 mg (140 mg\*3 capsules taken together at one time).
Study: NCT03987646

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-staged vestibular fresh socket therapy
Description: a slowly resorbable membrane shield is placed above the labial plate of bone so that when the thin labial plate started its resorption process the shield remains till a complete gap fill occurred thus leading to a thicker labial plate of bone or it preserves the socket architecture until a complete bone fill occurred inside the socket
Study: NCT05063006

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary exercise tests with maintained baseline optimal pump speed settings.
Description: Optimal resting LVAD speed settings is defined as periodic aortic valve opening while maintaining the central position of the intraventricular septum, minimizing mitral regurgitation, and preserving the mean systemic blood pressure above 65 mmHg. The aim is to achieve an aortic valve opening ratio of around 25-33% by changing the pump speed at resting conditions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test with gradually increased pump speed depending on live echocardiographic imaging.
Description: During the modified speed exercise, when the aortic valve opening ratio rises above 50%, the pump speed is increased by 100 revolutions per minute (RPM). As the aortic valve remains closed the RPM is lowered by 100. Speed increment is not greater than 100 RPM per 45 seconds to enable an echocardiographic analysis of resulting changes and prevent suction events. There is no determined target speed, neither per time period nor maximal.
Study: NCT02794363

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Autologous platelet rich plasma
Description: 5cc of autologous platelet rich plasma derived from 50cc of whole blood will be injected into vulvar skin.
Study: NCT01888536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Limaprost

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Limaprost

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo(for Pregabalin)
Description: mimic Pregabalin 75mg capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo(for Limaprost)
Description: mimic Limaprost tablet
Study: NCT02039219

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg Obeticholic Acid (OCA)
Description: 10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 6 weeks.
Study: NCT04098367

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIVITY
Description: Extended vision intraocular lens intended for primary implantation for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed by extracapsular cataract extraction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SYMFONY
Description: Extended range of vision intraocular lens indicated for primary implantation for the visual correction of aphakia in adult patients with less than 1.00 diopter of pre-existing corneal astigmatism in whom a cataractous lens has been removed

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AT LARA
Description: Extended depth of focus intraocular lens indicated for implantation for the visual correction of aphakia in patients with and without presbyopia in whom a cataractous lens has been removed by extracapsular cataract extraction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Cataract removal by routine small incision surgery
Study: NCT04198467

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: Platelet rich plasma : 100 billion platelets in 10 ml of plasma(PRP) administered intra-articular

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hyaluronic Acid
Description: Hyaluronic acid :Four ml of high-molecular-weight hyaluronic acid with a concentration of 22mg/ml injected intra-articular
Study: NCT04275167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tethered Capsule Endomicroscope/Trans Nasal Endomicroscope
Description: Either the Tethered Capsule Endomicroscope or the Transnasal Endomicroscope will be deployed in the subject. Once the capsule is swallowed /TNE device is inserted, the device will naturally be moved to the duodenum via peristalsis. Once in the duodenum, imaging will be performed. For subjects receiving the TNE device, brushing samples will be collected through the introduction tube.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tethered Capsule Endomicroscope/Trans Nasal Endomicroscope
Description: Either the Tethered Capsule Endomicroscope or the Transnasal Endomicroscope will be deployed in the subject. Once the capsule is swallowed /TNE device is inserted, the device will naturally be moved to the duodenum via peristalsis. Once in the duodenum, imaging will be performed. For subjects receiving the TNE device, brushing samples will be collected through the introduction tube.
Study: NCT03395600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B1S5
Description: Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B125S5
Description: Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.125% as the test dose. After 3 min, 10 ml of 0.125% bupivacaine epidural was injected
Study: NCT03744429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Participants will be provided with meals that follow a Mediterranean meal plan.
Study: NCT03036462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron
Description: i.v. iron administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: i.v. NaCl administration
Study: NCT04098367

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Cataract removal by routine small incision surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Cataract removal by routine small incision surgery
Study: NCT03395600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B1S10
Description: Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 10µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
Study: NCT01406106

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant stanol esters
Description: The administration of a dairy product in the form of liquid yoghurt, marketed in Spain, that contains 2 g per container of plant stanol esters: sitostanol and campestanol (AHA recommended dose - 1.5 to 3 g). The enriched product and the placebo will have the same characteristics (composition and outward appearance), but the placebo will not contain stanol esters. The dose will be one container a day, after the main meal, for 24 months. The participants may continue with their previously prescribed lipid-lowering treatment and new treatment needed for this disease or for other diseases. Composition per container: proteins 1.8 g, carbohydrates 9.8 g, fat (except stanol) 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg. The control group will receive one unit a day of yoghurt not supplemented with stanol esters that has a similar appearance to the enriched yoghurt.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Plant stanol esters
Description: The administration of a dairy product in the form of liquid yoghurt, marketed in Spain, that contains 2 g per container of plant stanol esters: sitostanol and campestanol (AHA recommended dose - 1.5 to 3 g). The enriched product and the placebo will have the same characteristics (composition and outward appearance), but the placebo will not contain stanol esters. The dose will be one container a day, after the main meal, for 24 months. The participants may continue with their previously prescribed lipid-lowering treatment and new treatment needed for this disease or for other diseases. Composition per container: proteins 1.8 g, carbohydrates 9.8 g, fat (except stanol) 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg. The control group will receive one unit a day of yoghurt not supplemented with stanol esters that has a similar appearance to the enriched yoghurt.
Study: NCT03163563

Intervention type: DEVICE
Intervention: Easywarm
Description: Warming blanket

Intervention type: DEVICE
Intervention: BairHugger
Description: Patient warming mattress with continuous warm air.
Study: NCT01412606

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: scratching
Description: scratching endometrium on day 21-26 of a spontaneous menstrual cycle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scratching
Description: scratching endometrium on day 21-26 of a spontaneous menstrual cycle
Study: NCT04350619

Intervention type: OTHER
Intervention: Genetic screening. No therapeutic intervention
Description: Genetic screening using NGS technique. No therapeutic intervention
Study: NCT03927651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG
Description: Indocyanine green (ICG) is a Food and Drug (FDA)-approved tricarbocyanine dye that is fluorescent under near-infrared (NIR) light. ICG solutions for injection often contain sodium iodide. ICG is water soluble and when introduced intravenously, it is bound by plasma proteins, namely albumin. The intravascular half-life of ICG is 3-4 minutes with rapid hepatic clearance.
Study: NCT02389348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439
Description: Single oral doses of OZ439
Study: NCT02205190

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan

Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan/Rosuvastatin combination

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan/Rosuvastatin combination
Study: NCT02542293

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab +Tremelimumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel + carboplatin
Description: Chemotherapy Agents

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + cisplatin
Description: Chemotherapy Agents

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + carboplatin
Description: Chemotherapy Agents

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed + cisplatin
Description: Chemotherapy Agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed + carboplatin
Description: Chemotherapy Agent
Study: NCT03484143

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Neuro RX Gamma device
Description: Twenty minute treatment session, 6 days a week for 24 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Neuro RX Gamma device
Description: Twenty minute treatment session, 6 days a week for 24 weeks
Study: NCT01974349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib (oral)
Description: Volunteers will receive: 75 mg selumetinib oral dose in a fasted state (Treatment A) followed by a second 75 mg selumetinib oral dose in the fed state (Treatment B) with a washout period of at least 7 days between doses, or: 75 mg selumetinib oral dose in the fed state (Treatment B) followed by a second 75 mg selumetinib oral dose in the fasted state (Treatment A) with a washout period of at least 7 days between doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib (oral)
Description: Volunteers will receive: 75 mg selumetinib oral dose in a fasted state (Treatment A) followed by a second 75 mg selumetinib oral dose in the fed state (Treatment B) with a washout period of at least 7 days between doses, or: 75 mg selumetinib oral dose in the fed state (Treatment B) followed by a second 75 mg selumetinib oral dose in the fasted state (Treatment A) with a washout period of at least 7 days between doses.
Study: NCT01932632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Minimization
Description: Series of specific medication reviews done by attending MD using standardized study protocol forms and MD's clinical assessment.
Study: NCT02738307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altitude exposure
Description: Acute high altitude exposure followed by 8 day acclimatization and re-exposure for 8 days after 6 days at low altitude
Study: NCT05225753

Intervention type: DIAGNOSTIC_TEST
Intervention: hemoglobin serum value
Description: post-operative anemia evaluated with hemoglobin serum value

Intervention type: DIAGNOSTIC_TEST
Intervention: hemoglobin serum value
Description: post-operative anemia evaluated with hemoglobin serum value
Study: NCT01261689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine/ Sufentanil according to local hospital protocol
Description: according to local hospital protocol

Intervention type: OTHER
Group type: OTHER
Intervention: Care-as usual pain treatment
Description: Pain treatment only on request of the women in labour. Treatment is given according to local hospital protocol.
Study: NCT05225753

Intervention type: DIAGNOSTIC_TEST
Intervention: hemoglobin serum value
Description: post-operative anemia evaluated with hemoglobin serum value
Study: NCT03902457

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary sinus augmentation
Description: Maxillary sinus augmentation procedures have become increasingly popular procedures before placement of dental implants in posterior maxillae that have suffered severe bone loss due to sinus pneumatization, alveolar bone atrophy, or trauma.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary sinus augmentation
Description: Maxillary sinus augmentation procedures have become increasingly popular procedures before placement of dental implants in posterior maxillae that have suffered severe bone loss due to sinus pneumatization, alveolar bone atrophy, or trauma.
Study: NCT00177177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-carnosine (dietary supplement)
Description: an antioxidant and AGE inhibitor, 500 mg/day, titration each week to reach 2000 mg/day in 4 weeks L-Carnosine is a dietary supplement
Study: NCT02101593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20
Study: NCT03695952

Intervention type: DRUG
Intervention: Nivolumab or pembrolizumab
Description: Nivolumab 3 mg/kg intravenous every 2 weeks; Pembrolizumab 200 mg intravenous every 3 weeks

Intervention type: DRUG
Intervention: Nivolumab or pembrolizumab
Description: Nivolumab 3 mg/kg intravenous every 2 weeks; Pembrolizumab 200 mg intravenous every 3 weeks
Study: NCT04152551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate Oral Tablet
Description: Oral bisphosphonate
Study: NCT04597125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Participants will receive Radium-223 (BAY88-8223) every 4 weeks for a total of 6 administrations via intravenous (IV) injection
Study: NCT00177177

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-carnosine (dietary supplement)
Description: an antioxidant and AGE inhibitor, 500 mg/day, titration each week to reach 2000 mg/day in 4 weeks L-Carnosine is a dietary supplement
Study: NCT01203293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior based therapy
Description: 15-20 individual psychotherapy sessions
Study: NCT03961659

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutid
Description: Liraglutid will be titrated from 0.6mg/day to 1.8mg/day during the first 2 weeks, if well tolerated. All patients will also continue on their existing dose and regimen of metformin throughout the study.
Study: NCT04424628

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low dose radiotherapy A
Description: Low dose radiotherapy was 0.5 Gy in 6 fractions. Evaluation of pain and Quality of Life in 8-12 weeks. If no pain releave the patient is randomized to 3 or 6 Gy again

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low dose radiotherapy B
Description: Low dose radiotherapy was 0.5 Gy in 6 fractions. Evaluation of pain and Quality of Life in 8-12 weeks. If no pain releave the patient is treated with 6 Gy again
Study: NCT04597125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAH therapy
Description: Participants will receive continuous NAH (either Abiraterone acetate plus prednisone/prednisolone \[AAP\] or enzalutamide) by mouth (per os) daily
Study: NCT03420404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TCM physician involved collaborative care model (TCMCMC)
Description: TCM physician delivered acupuncture as well as history taking, physical examination, non-pharmacological advice and communications with rheumatologists.~Acupuncture procedures: After eliciting the deqi sensation, the needles will be left in place for 30 minutes. The acupuncture treatment will be done 2-3 times a week, with 5 sessions constituting a treatment course. There will be a break of 1 week in between each acupuncture course. Patients in the intervention arm will undergo 2 treatment courses (or 10 sessions) in total.
Study: NCT01637636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon
Description: 20mg, oral capsule, once, Days 1 and 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon
Description: 20mg, oral capsule, once, Days 1 and 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600mg, oral capsules (2 x 300mg), once daily (QD), Days 2-11
Study: NCT01203293

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual is an active comparator group in which patients are provided referrals to specialty mental health care services or can use any primary or specialty care services available to them in usual care.
Study: NCT02595346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: endothelial function is assessed by measuring the flow mediated dilatation of humeral artery in response to ischemia. the dilatation is evaluated by echotracking.~glycocalyx thickness is measured by the study of sublingual microcirculation with SDF imaging.~oxydative, inflammatory and coagulation parameters is assessed on plasma samples.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: endothelial function is assessed by measuring the flow mediated dilatation of humeral artery in response to ischemia. the dilatation is evaluated by echotracking.~glycocalyx thickness is measured by the study of sublingual microcirculation with SDF imaging.~oxydative, inflammatory and coagulation parameters is assessed on plasma samples.
Study: NCT01637636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: 400mg, oral tablets (2 x 200mg), once daily (QD), Days 2-6